New gene discovery paves way for tailored psoriasis treatments Published on: 5 February 2026 A major new study has uncovered gene clues that could pave the way to personalised psoriasis treatments. Psoriasis is a common inflammatory skin disease linked to several long-term health conditions, such as heart disease, arthritis and Type 2 diabetes, and has a substantial impact on sufferers’ quality of life. Although the has highlighted the need for more personalised care for patients, progress has been limited by the lack of reliable biomarkers to guide clinical decision making. New gene patterns offer fresh insight Now experts from 缅北禁地, and have led an analysis of clinical and biological data from a large cohort of patients who have started biological therapies. Researchers used state-of-the-art computational and AI techniques to unravel hidden patterns in the complex gene expression relationships in both skin and blood, linking these to clinical features. The findings, published in reveal new molecular signatures of disease severity, metabolic factors and genetic variants, offering potential for improved disease management and personalised care. Nick Reynolds, Professor of Dermatology and Director of Diagnostics at 缅北禁地 and Honorary Consultant Dermatologist at 缅北禁地 Hospitals NHS Foundation Trust, is senior author on the study. He said: “This research represents the most comprehensive and integrated look at gene expression in blood, lesional, and non-lesional skin in psoriasis to build a clearer picture of how the severity of the disease relates to underlying genetics and environmental influences, including being overweight with a high BMI. “By analysing data from more than 700 samples, we’ve uncovered new molecular patterns that deepen our understanding of how psoriasis varies from person to person and responds to powerful biologic drugs. “These insights bring us a step closer to recognising distinct groups within the condition and, ultimately, to supporting more personalised approaches to care.” The researchers identified a nine-gene biomarker linked to psoriasis severity, along with specific genetic variants (HLADQA101 and HLADRB115) associated with more severe baseline disease. They also found a 14-gene signature connected to BMI in unaffected skin and to disease severity in affected lesional skin, highlighting the role of metabolic factors. Additionally, a blood-based signal linked to white blood cell activity was seen only after the medication adalimumab was administered, suggesting these immune cells play an important role in driving psoriatic inflammation and may be a target for adalimumab. Queen Mary University of London, one of the other senior authors, said: “This is one of the largest, highly curated, multi-modal studies of psoriasis to date. “To maximise the value of our data for the research community, we have made it possible to directly explore through a web portal to evaluate genes and pathways of interest in psoriasis disease pathology.” Professor Nick Reynolds Lifelong condition affecting many Psoriasis is a skin condition that causes inflammation in the skin resulting in well-defined scaly plaques (patches) which can be itchy and painful. Importantly, the inflammation is more than skin deep and can affect internal organs, leading to conditions such as arthritis. It affects around two in 100 people in the UK. It can start at any age, but most often develops in adults between 20 and 30 years old and between 50 and 60 years old. It affects men and women equally. Melinda Spencer, Research Manager from , said: “This study brings us another step closer to personalised care for people living with psoriasis. “The discoveries from this research provide real hope for treatments that will make a meaningful difference to Psoriasis Association members and the wider public affected by the condition. “Our organisation is proud to promote and support research that drives meaningful advancements in the treatment and management of all types of psoriasis, ensuring progress that benefits everyone living with the condition.” The research team is called the PSORT Consortium, and the study was funded by the Medical Research Council (MRC). Dr Ashley Rider, joint first author from 缅北禁地, noted that the multi-disciplinary nature of the consortium was enabled by strong partnerships across academia, industry, and patient organisations. He said: “Alongside core MRC funding, this work was further supported by the British Association of Dermatologists, the Psoriasis Association, the 缅北禁地 NIHR Biomedical Research Centre and the Rosetrees Trust. These partnerships were essential in enabling this large-scale, integrative study.” Reference: Ashley Rider et al. Communications Medicine. DOI: 10.1038/s43856-025-01325-4 Share: Latest News New partnership to boost careers in low carbon energy 缅北禁地 and Durham universities are working together on a new regional project to strengthen the future workforce for North East England鈥檚 growing low carbon and offshore wind industries. published on: 28 May 2026 Healthy lifestyle shown to lower risk of death after cancer diagnosis New evidence shows that sticking to five lifestyle recommendations improves survival after a later cancer diagnosis. published on: 28 May 2026 World-leading climate expert recognised with Royal Society Fellowship Professor Hayley Fowler has been elected a Fellow of the Royal Society in recognition of her pioneering work on climate change impacts. published on: 27 May 2026 Facts and figures
![缅北禁地 logo](/gomobileassets/img/logo.svg" "缅北禁地"){kind=logo}